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Wereporttwocasesofyoungmeninwhomacuteheartfailureduetomyocarditiswasdiagnosed.Thepatientshadbeentransferred
to the intensive care unit (ICU) with commencing symptoms of acute heart failure and consecutive multiorgan failure for further
treatment and to evaluate the indication for implantation of a ventricular assist device or for high urgent orthotopic heart
transplantation. In both patients, the If-channel inhibitor ivabradine was administered oﬀ-label to provide selective heart rate
reduction, and thus support hemodynamic stabilization. Though currently considered oﬀ-label use in patients suﬀering from
severe hypotension and acute heart failure, the use of ivabradine may beneﬁcially inﬂuence outcome by allowing optimization of
the patient’s heart rate concomitant to initial measures of clinical stabilization.
1.Introduction
Although the energy-eﬃcient mechanisms of heart rate
reduction are apparent, in the event of acute heart failure due
to myocarditis, the utilization of this therapeutic strategy has
only playeda minor role. Due tothe hypotensive characterof
beta-receptor-blockers and class IV antiarrhythmics, physi-
cians have been constrained to administering these agents
subsequent to stabilizing the patient and not in the advent
of acute distress [1]. Ivabradine is a selective heart-rate-
lowering agent that acts on the sinoatrial node without the
undesired eﬀect of hypotension. By inhibiting the activity
of the If channel, ivabradine decelerates the gradient of
diastolic depolarisation and by this reduces the intrinsic
pacemaker activity in the sinoatrial node. Due to this unique
mechanism of heart rate reduction without inﬂuence on
myocardialcontractility,itisconceivablethativabradinemay
also play a key role in the therapy of acute heart failure.
2. Case Presentation
We report two cases of young men in whom acute heart
failure due to myocarditis was diagnosed. The patients
had been transferred to the intensive care unit (ICU)
of our department with commencing symptoms of acute
heart failure and consecutive multiorgan failure for further
treatment and to evaluate the indication for implantation of
a ventricular assist device or for high urgent orthotopic heart
transplantation. In both patients, the If-channel inhibitor
ivabradine was administered oﬀ-label to provide selective
heart rate reduction, and thus support hemodynamic stabi-
lization.
Patient no. 1, a previously healthy 18-year-old man, was
transferred to the ICU of our department of cardiology
from a secondary hospital for further treatment. Despite
all attempts to stabilize the patient at the prior hospital,
including therapy with inotropics, levosimendan, and high
doses of furosemide i.v., clinical symptoms of right and left
heart failure had signiﬁcantly worsened within days. Recent
clinical history indicated an onset of ﬂu-like symptoms
including dry cough and fever continuing for seven days
followed by progression of dyspnoea, which led to the initial
hospital admission ten days before. At the time of transfer
to our ICU, the patient suﬀe r e da c u t eh e a r tf a i l u r ew i t hs u b -
sequent acute renal failure and severe liver and pulmonary2 Case Reports in Medicine
congestion. The patient’s mean heart rate was 115bpm,
and mean blood pressure was 62 (85/50)mmHg (Figure 1).
Cardiac catheterization showed normal coronary arteries
and a globally dilated heart with severely impaired systolic
left ventricular (LV) function. LV ejection fraction measured
20% in echocardiography. The patient rejected a myocardial
biopsy under the aspect of the elevated risk of bleeding
subsequent to his liver congestion; therefore, histological
examinations were not possible. Although cardiac MRI
ruled out myocardial edema, epicardial late enhancement
was detected in the basal inferolateral region which was
interpreted as an unspeciﬁc postmyocarditis phenomenon
(Figure 2). As further circulatory support was required,
intra-aortic balloon counterpulsation (IABP) was initiated,
and inotropic treatment with dobutamine was increased to
10µg/kg/min. Cardiac output measured 4.1L/min initially
and raised to a maximum of 6.0L/min (stroke volume
46.2mL/beat) under increased dobutamine therapy. Though
thepatientwassuccessfullyweanedfromIABPafterﬁvedays,
thedobutaminedosecouldnotbereducedandconsecutively
led to sinus tachycardia (mean heart rate 130bpm). After
receiving approval of the institutional review body and the
patient’s informed consent, the If-channel inhibitor ivabra-
dinewasadministeredoﬀ-labeltoprovideselectiveheartrate
reduction. Ivabradine therapy was initiated with 5mg twice
daily orally. One day after ivabradine therapy was started,
the patient’s heart rate reduced signiﬁcantly to 75bpm, and
blood pressure increased to 110/60mmHg. Concordant to
the prompt improvement in hemodynamic parameters, an
improvement of diuresis was achieved. Over the follow-
ing three days, the patient was successfully weaned from
catecholamines, and the patient’s body weight markedly
reduced. Invasive measurements revealed a cardiac output
of 5.8L/min (stroke volume 72.5mL/beat). In echocardiog-
raphy, left ventricular ejection fraction increased minimally
from 20 to 25%. In addition, we observed a lowering
of N-terminal probrain natriuretic peptide (NTproBNP)—
from 6237ng/L to 3920ng/L, which corresponded well with
the noticeable clinical improvements. After discharge, the
patient underwent close clinical followup at our specialized
outpatient heart failure clinic. After gradual uptitration of
a beta-receptor-blocker (carvedilol), ivabradine was reduced
after approximately 9 months (274 days) without complica-
tions. As of this writing, clinical followup of patient no. 1 is
available up to 463 days after initiation of ivabradine. During
this last outpatient visit, the patient showed no functional
limitations (NYHA I), and his NTproBNP reduced to a
nearly normal value of 192ng/L (age-dependant normal
values are below 125ng/L).
Patient no. 2, a previously healthy 28-year-old man, was
transferred to our ICU by a collaborating tertiary hospital
to evaluate the indication for implantation of a ventricular
assist device or for high urgent orthotopic heart trans-
plantation. At arrival, the patient presented commencing
symptoms of acute heart failure and consecutive multiorgan
failure,includingmildpancreatitis,acuterenalfailurerequir-
ingdailydialysis,andsevereliverandpulmonarycongestion.
His mean heart rate was 120bpm. In spite of previous
treatment with inotropics and levosimendan over ﬁve days,
clinical stabilization had so far been unsuccessful. The
patient’s recent clinical history revealed ﬂu-like symptoms
including cough, diarrhoea, and fever which began one week
prior to his initial admission. His chest X-ray showed no
signs of pneumonia, and microbiological tests were negative.
In echocardiographic evaluation, an ejection fraction of
10% and an increased left ventricular enddiastolic diameter
of 75mm were measured (body-surface-adapted normal
values for men are below 56mm). Cardiac catheterization
ruled out coronary heart disease. Multiple endomyocardial
biopsies taken during the procedure conﬁrmed the diag-
nosis of inﬂammatory cardiomyopathy with mononuclear
inﬁltration in histological analysis (Figure 3). As in the case
of patient no. 1, weaning from inotropic support (dobu-
tamine 3.7µg/kg/min) was primarily unsuccessful, and sinus
tachycardia remained a relevant clinical symptom (Figure 1).
The patient gave informed consent to an oﬀ-label therapy
with ivabradine to treat sinus tachycardia selectively. Within
24 hours, after we initiated ivabradine therapy (5mg twice
daily orally), the patient’s heart rate had lowered to 89bmp
and further to 75bpm in the following day. In addition
to the noticeable heart rate reduction within 48 hours, the
patient’s blood pressure stabilized at 120/65mmHg, and
inotropic therapy with dobutamine could be discontinued.
Invasive measurements to calculate cardiac output were not
performed in this patient. Repeat echocardiography after the
initiation of ivabradine revealed a consistent left ventricu-
lar ejection fraction of 10%. Sequential measurements of
NTproBNP taken shortly after admission, then after clinical
improvement, demonstrated a reduction of NTproBNP
value from 81,195ng/L to 28,161ng/L. Ivabradine therapy
was discontinued, and beta-receptor-blocker therapy was
gradually uptitrated after approximately 1 month (35 days)
without clinical complications. During the follow-up period
of 232 days, the patient further recovered and currently has
no functional limitations (NYHA I). NTproBNP reduced to
183ng/L.
3. Discussion
Therangeof indications forivabradine includes treatmentof
stable angina pectoris in patients with sinus rhythm and, in
conjunction to beta-receptor-blockers, treatment of patients
with chronic heart failure [2, 3]. Of the relatively few adverse
drug reactions described in the two largest randomized
trials which evaluated ivabradine in these cohorts, transient
phosphenes (visual sensations of enhanced brightness) and
bradycardiaaccountedforthemostfrequentdrug-associated
complications. Fortunately, these adverse drug eﬀects only
rarely led to discontinuation of pharmacotherapy. In the
absence of evidence from other, more far-reaching clinical
trials, ivabradine is currently contraindicated in patients
suﬀering from severe hypotension and/or acute heart failure.
However, it is conceivable that this novel agent may be
advantageous through more than one mechanism in exactly
these speciﬁc situations, ﬁrst by counteracting dobutamine-
induced sinus tachycardia, which frequently limits the suc-
cess of stabilization in the case of acute heart failure. InCase Reports in Medicine 3
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Figure 1: Therapy and hemodynamic parameters of patient no. 1 and no. 2 throughout the ﬁrst nine days of intensive care treatment. IABP:
intra-aortic balloon counterpulsation.
(a) four-chamber view (b) short-axis view
Figure 2: Epicardial late enhancement in the basal inferolateral region in cardiac MRI.
contrast to beta-receptor-blockers or class IV antiarrhyth-
mics such as Diltiazem or Verapamil, ivabradine does not
share their hypotensive character which largely limits their
administration in the advent of acute heart failure. Secondly,
although substantial clinical evidence is pending, experience
from one preclinical study suggest that ivabradine may play a
modulatingroleinperivascularandinterstitialinﬂammatory
reactions in acute myocarditis and in myocardial infarction
[4].
A similar case of acute heart failure and dobutamine-
induced sinus tachycardia has previously been reported.
The authors described beneﬁcial hemodynamic eﬀects in a4 Case Reports in Medicine
Figure 3: Inﬂammatory cardiomyopathy with mononuclear inﬁl-
tration in histopathological analysis.
patient with severe ischemic cardiomyopathy. The patient’s
heart rate decreased from 114 to 75bpm after initiation of
ivabradine, and a discrete increase in stroke volume was
noticed [5]. Others have described the use of ivabradine in
a patient with acute myocardial infarction and cardiogenic
shock. Despite successful recanalization of the left main
coronary artery, the patient’s heart rate was 120bpm.
Weaning of IABP and inotropic medical treatment (drug
not speciﬁed) was not possible due to severe hypotension.
Forty-eight hours after introducing ivabradine to the drug
regime, heart rate reduced to 80bpm, and the patient was
successfully weaned from IABP and inotropics [6]. Mulder
et al. were the ﬁrst to demonstrate preservation of cardiac
output despite the decrease in heart rate after administration
of ivabradine in a rat model of chronic heart failure. The
authors hypothesized that prolongation of the diastolic
phase through the administration of ivabradine increases
left ventricular ﬁlling, and thus enhances stroke volume
despite heart rate reduction [7]. In a corresponding clinical
study, hemodynamic eﬀects of ivabradine were evaluated in
ten patients with advanced heart failure (NYHA III). The
authors reported an increase of stroke volume of up to 51%
after initiation of ivabradine therapy. Similarly, we detected
an increase of stroke volume (+36%) in patient no. 1 despite
heart rate reduction and simultaneous weaning of inotropic
support [8].
Within the limitations of data obtained from just two
patients, this present experience can only be hypothesis
generating. We suggest that selective heart rate reduction
with ivabradine may beneﬁcially inﬂuence the outcome of
patients presenting with the above-mentioned symptoms in
the course of myocarditis by allowing optimization of the
patient’sheartrateconcomitanttoinitialmeasuresofclinical
stabilization.
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